Orencia — Total Revenues
Bristol-Myers Squibb Orencia — Total Revenues increased by 0.1% to $964.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 3.0%, from $936.00M to $964.00M. Over 3 years (FY 2021 to FY 2024), Orencia — Total Revenues shows an upward trend with a 3.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market demand and successful patient retention, while a decrease may signal increased competition from biosimilars or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total global net sales generated from the Orencia product line, a biologic therapy primarily...
Peer comparison
Similar to other major biologic drug revenue streams in the pharmaceutical industry, performance is typically compared against peer immunology franchises and market penetration rates for autoimmune therapies.
bmy_segment_orencia_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $814.00M | $870.00M | $864.00M | $792.00M | $876.00M | $883.00M | $913.00M | $764.00M | $927.00M | $925.00M | $985.00M | $798.00M | $948.00M | $936.00M | $1.00B | $770.00M | $963.00M | $964.00M |
| QoQ Change | — | +6.9% | -0.7% | -8.3% | +10.6% | +0.8% | +3.4% | -16.3% | +21.3% | -0.2% | +6.5% | -19.0% | +18.8% | -1.3% | +6.8% | -23.0% | +25.1% | +0.1% |
| YoY Change | — | — | — | — | +7.6% | +1.5% | +5.7% | -3.5% | +5.8% | +4.8% | +7.9% | +4.5% | +2.3% | +1.2% | +1.5% | -3.5% | +1.6% | +3.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's orencia — total revenues?
- Bristol-Myers Squibb (BMY) reported orencia — total revenues of $964.00M in Q3 2025.
- How has Bristol-Myers Squibb's orencia — total revenues changed year-over-year?
- Bristol-Myers Squibb's orencia — total revenues increased by 3.0% year-over-year, from $936.00M to $964.00M.
- What is the long-term trend for Bristol-Myers Squibb's orencia — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's orencia — total revenues has grown at a 3.7% compound annual growth rate (CAGR), from $3.31B to $3.68B.
- What does orencia — total revenues mean?
- Total global sales generated by the Orencia drug product line.